Non-alcoholic steatosis and steatohepatitis – editorial

1. Neuschwander -⁠ Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37 : 1202 –⁠ 1219.

2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49 : 306 –⁠ 317.

3. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999 –⁠ 2004. Gastroenterology 2007; 133 : 1814 –⁠ 1820.

4. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver dinase: a feature of the metabolic syndrome. Diabetes 2001; 50 : 1844 –⁠ 1850.

5. Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilisation in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23 : 201 –⁠ 229.

6. Day C, James O Steatohepatitis: a tale of two „hits“? Gastroenterology 1998; 114 : 842 –⁠ 845.

7. Diehl AM, Li ZP, Lin HZ. Cytokines and the pathogenesis of non‑alcoholic steatohepatitis. Gut 2005; 54 : 303 –⁠ 306.

8. Hui J, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF‑alfa or adiponectin? Hepatology 2004; 40 : 19 –⁠ 22.

9. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for he­patic steatosis in Northern Italy. Ann Intern Med 2000; 132 : 112 –⁠ 117.

10. Caldwell SH, Oelsner DH, Lezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29 : 664 –⁠ 669.

11. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3 : 1260 –⁠ 1268.

12. Cortez -⁠ Pinto H, Baptista A, Camil E et al. Nonalcoholic steatohepatitis clinicopathological comparison with alcoholic he­patitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41 : 172 –⁠ 179.

13. Dousa M, Zima T, Bruha R et al. Sensitivity and specificity of CDT in the evaluation of alcohol abuse in cirrhotic patients. Gut 2006; 55 (Suppl. No V): A 307.

14. Dunn W, Angulo P, Sanderson S et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131 : 1057 –⁠ 1063.

15. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 : 1413 –⁠ 1419.

16. Bugianesi E, Manzini P, D’Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39 : 179 –⁠ 187.

17. Loria P, Lonardo A, Leonardi F et al. Non -⁠ organ -⁠ specific autoantibodies in non­alcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48 : 2173 –⁠ 2181.

18. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistence and beta‑cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 : 412 –⁠ 419.

19. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94 : 2467 –⁠ 2474.

20. Ekstedt M, Franzen LE, Mathiesen UL et al. Long‑term follow‑up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 : 865 –⁠ 873.

21. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28‑year follow‑up. Hepatology 2010; 51 : 595 –⁠ 602.

22. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27 : 103 –⁠ 107.

23. Bellentani S, Dalle Grave R, Suppini Aet al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008; 47 : 746 –⁠ 754.

24. Angelico F, Burattin M, Alessandri C et al. Drugs improving insulin resistance for non‑alcoholic fatty liver disease and/ or non‑alcoholic steatohepatitis. Cochrane Database Syst Rev 2007: CD005166.

25. Capanni M, Calella F, Biagini MR et al. Prolonged n -⁠ 3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‑alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23 : 1143 –⁠ 1151.